How much are target stocks?
Target stock price target raised to $353 from $305 at Deutsche Bank Mar. 2, 2022 at 7:53 a.m. ET by Tomi Kilgore Target stock price target raised to $290 from $262 at J.P. Morgan
What is target stock price?
$350 Price Target for Nvidia Stock Is Ambitious But Possible
- Nvidia ( NVDA) will face headwinds, no doubt, but the company remains a tech-market leader and innovator.
- Two Wall Street experts are preparing for Nvidia stock to move higher.
- Investors should buy some Nvidia shares on the dip.
What is target share price?
Tata Motors TATAMOTORS Monthly share price target
- Tata Motors Monthly share price target downside target 1: 401.42
- Tata Motors Monthly share price target downside target 2: 348.78
- Tata Motors Monthly share price target upside target 1: 510.72
- Tata Motors Monthly share price target upside target 2: 567.38
What are stock price targets?
Analysts have given the company’s stock an average 52-week price target of $7.33, forecast between a low of $1.00 and high of $13.00. Looking at the price targets, the low is 45.95% off current price level while to achieve the yearly target high ...
See more
Is VKTX stock a good buy?
Is Viking Therapeutics Stock a good buy in 2022, according to Wall Street analysts? The consensus among 2 Wall Street analysts covering (NASDAQ: VKTX) stock is to Buy VKTX stock.
How high will Viking Therapeutics Stock go?
Stock Price Forecast The 9 analysts offering 12-month price forecasts for Viking Therapeutics Inc have a median target of 15.00, with a high estimate of 30.00 and a low estimate of 10.00. The median estimate represents a +331.03% increase from the last price of 3.48.
Is Viking Therapeutics still a buy?
Viking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
What does Viking Therapeutics do?
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.
Is CymaBay Therapeutics a good buy?
CymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Where is Viking Therapeutics located?
San Diego, CaliforniaViking Therapeutics is located in San Diego, California, United States .
What is VK2809?
Our lead candidate, VK2809, is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promise for the treatment of metabolic disorders, including non-alcoholic steatohepatitis (NASH).
Should I buy or sell Viking Therapeutics stock right now?
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currentl...
What is Viking Therapeutics' stock price forecast for 2022?
7 brokerages have issued 12 month price objectives for Viking Therapeutics' shares. Their forecasts range from $10.00 to $21.00. On average, they a...
How has Viking Therapeutics' stock price performed in 2022?
Viking Therapeutics' stock was trading at $4.60 at the beginning of the year. Since then, VKTX stock has decreased by 51.5% and is now trading at $...
When is Viking Therapeutics' next earnings date?
Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for...
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics, Inc. (NASDAQ:VKTX) announced its quarterly earnings data on Wednesday, April, 27th. The biotechnology company reported ($0.21)...
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the following people: Dr. Brian Lian Ph.D. , Pres, CEO & Director (Age 56, Pay $872k) Mr. Gregory...
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include Evolus (EOLS) , MorphoSys (MOR) , Catalyst Pharmaceuticals (CPRX) , Pharvaris (P...
What other stocks do shareholders of Viking Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA) ,...
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.0...
When will Viking Therapeutics release its earnings?
How much does Viking Therapeutics make?
Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021. View our earnings forecast for Viking Therapeutics.
Premium Research for VKTX
Viking Therapeutics has a market capitalization of $450.64 million. The biotechnology company earns $-39,490,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
